The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi).
 
Andrea B. Apolo
No Relationships to Disclose
 
Amir Mortazavi
Honoraria - Motive Medical Intelligence
Research Funding - Acerta Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Roche (Inst); Seagen (Inst)
 
Zishuo Ian Hu
No Relationships to Disclose
 
Joseph Schonhoft
Employment - Epic Sciences
Stock and Other Ownership Interests - Epic Sciences
 
Lincy Chu
Employment - Epic Sciences
 
Amanda K. L. Anderson
Employment - Epic Sciences
 
Yipeng Wang
Employment - Epic Sciences
Stock and Other Ownership Interests - Epic Sciences
 
Ryan Dittamore
Employment - Epic Sciences
Leadership - Epic Sciences
Stock and Other Ownership Interests - Epic Sciences
Patents, Royalties, Other Intellectual Property - Patents Pending
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Primo Lara
Honoraria - Pfizer
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; CellMax Life; Exelixis; Foundation Medicine; Genentech/Roche; Janssen; Merck; Nektar; Pfizer; Turnstone Bio
Research Funding - Aragon Pharmaceuticals (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Incyte (Inst); Janssen Biotech (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Polaris (Inst); TRACON Pharma (Inst)
 
Mark N. Stein
Consulting or Advisory Role - Exelixis; Exelixis; Merck Sharp & Dohme
Research Funding - Advaxis (Inst); Bristol-Myers Squibb (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Seagen (Inst); Suzhou Kintor Pharmaceuticals (Inst); Xencor (Inst)
 
Seth M. Steinberg
No Relationships to Disclose
 
Christian Mayfield
No Relationships to Disclose
 
Lisa M. Cordes
No Relationships to Disclose
 
Marissa Mallek
No Relationships to Disclose
 
Rene Costello
No Relationships to Disclose
 
Carlos Diaz
No Relationships to Disclose
 
Jane B Trepel
No Relationships to Disclose
 
Donald P. Bottaro
No Relationships to Disclose